Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Neonc Technologies, Inc.
Bristol-Myers Squibb
Immatics US, Inc.
ImmunityBio, Inc.
University of Pittsburgh
University of Pittsburgh
Incyte Corporation
Incyte Corporation
Toray Industries, Inc
Purple Biotech Ltd.
Eli Lilly and Company
Molecular Templates, Inc.
Fate Therapeutics
Incyte Corporation
Duke University
MultiVir, Inc.
National Cancer Institute (NCI)